Mark Sheptoff Financial Planning, LLC Halozyme Therapeutics, Inc. Transaction History
Mark Sheptoff Financial Planning, LLC
- $182 Million
- Q4 2024
A detailed history of Mark Sheptoff Financial Planning, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Mark Sheptoff Financial Planning, LLC holds 85 shares of HALO stock, worth $4,981. This represents 0.0% of its overall portfolio holdings.
Number of Shares
85
Previous 85
-0.0%
Holding current value
$4,981
Previous $4,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
535Shares Held
122MCall Options Held
413KPut Options Held
154K-
Black Rock Inc. New York, NY17.6MShares$1.03 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$778 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$389 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$238 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.07MShares$180 Million0.05% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.16B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...